Capricor Therapeutics, Inc. (CAPR)

NASDAQ: CAPR · IEX Real-Time Price · USD
6.25
-0.04 (-0.64%)
At close: May 22, 2024, 4:00 PM
6.20
-0.05 (-0.80%)
After-hours: May 22, 2024, 5:15 PM EDT
-0.64%
Market Cap 198.82M
Revenue (ttm) 27.10M
Net Income (ttm) -24.31M
Shares Out 31.81M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 321,782
Open 6.29
Previous Close 6.29
Day's Range 6.10 - 6.35
52-Week Range 2.68 - 8.22
Beta 4.07
Analysts Strong Buy
Price Target 21.75 (+248.0%)
Earnings Date May 13, 2024

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 101
Stock Exchange NASDAQ
Ticker Symbol CAPR
Full Company Profile

Financial Performance

In 2023, CAPR's revenue was $25.18 million, an increase of 886.81% compared to the previous year's $2.55 million. Losses were -$22.29 million, -23.20% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $21.75, which is an increase of 248.00% from the latest price.

Price Target
$21.75
(248.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024–

9 days ago - GlobeNewsWire

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO,...

13 days ago - GlobeNewsWire

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...

14 days ago - GlobeNewsWire

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...

16 days ago - GlobeNewsWire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-

4 weeks ago - GlobeNewsWire

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventi...

2 months ago - GlobeNewsWire

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Presentation Highlights Positive 24-Month Results from HOPE-2 Open L...

2 months ago - GlobeNewsWire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 20...

2 months ago - GlobeNewsWire

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevent...

3 months ago - GlobeNewsWire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventio...

3 months ago - GlobeNewsWire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology c...

3 months ago - GlobeNewsWire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

-Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic-

4 months ago - GlobeNewsWire

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku--

5 months ago - GlobeNewsWire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Wou...

6 months ago - GlobeNewsWire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

7 months ago - GlobeNewsWire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

7 months ago - GlobeNewsWire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002's Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-

8 months ago - GlobeNewsWire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the tre...

8 months ago - GlobeNewsWire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002's Path Towards a Biologics License Application (BLA)-

8 months ago - GlobeNewsWire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for...

9 months ago - GlobeNewsWire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Mus...

10 months ago - GlobeNewsWire

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

10 months ago - GlobeNewsWire

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D.

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

10 months ago - GlobeNewsWire

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

-John Hopkins School of Medicine Clinical Director Joins Capricor's Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience-

11 months ago - GlobeNewsWire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function-

11 months ago - GlobeNewsWire